drugset / Trial / NCT04192682
Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
Immunotherapy combined with anti-angiogenic therapy can achieve better results in patients with second-line and above small cell lung cancer
Timeline
- Start
- 2019-05-08
- Primary completion
- 2021-03-01
- Completion
- 2021-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | — | — |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | — |